Do you want to read an article? Please log in or register.
Multimodal PET/CT-based PD-L1 status prediction in lung cancer via semi-supervised and unsupervised deep learning
Lung Cancer
Related content
Lung Cancer
Impact of Histology and PD-L1 Status on Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer a Systemic Review and Meta-analysis
Clin Lung Cancer
Choucair K, Jang H, Jalal SI, Hadid T, Uprety D, Kim S, Mamdani H
doi: 10.1016/j.cllc.2025.10.014
Lung Cancer
Explainable deep learning-based lung cancer diagnosis using clinically-guided local interpretable model-agnostic explanations
Sci Rep
Hassan SU, Abdulkadir SJ, Alhussian HS, Fayyaz AM, Al-Selwi SM, Khan U, Ismail AOA
doi: 10.1038/s41598-026-44127-x
Lung Cancer
Brain Metabolic Activity Measured by [(18)F]FDG PET/CT Predicts Survival in Patients with Advanced Non-Small Cell Lung Cancer
J Nucl Med
Auriac J, Lemoudda G, Hovhannisyan-Baghdasarian N, Pires M, Shiyam Sundar LK, Salamoun-Feghali P, Seban RD, Jehanno N, Nioche C, Luporsi M, Beyer T, Livartowski A, Girard N, Buvat I, Orlhac F
doi: 10.2967/jnumed.125.271400
RECOMMENDED
Lung Cancer
Real World Effectiveness of Durvalumab in Stage III Unresectable Non-small Cell Lung Cancer: What is the Role of PD-L1 Expression?
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Clin Lung Cancer
Kalkhoran HA, Verschueren MV, Peters BJM, van de Garde EMW, Smit EF, Bohringer S, Cohen D, Gulikers JL, Codrington H, Guchelaar HJ, Visser LE, Zwaveling J
doi: 10.1016/j.cllc.2025.07.009
Lung Cancer
PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial
Nat Commun
Zeng L, Ruan Z, Yan H, Qin H, Zeng Z, Zou C, Huang Z, Jiang W, Dai J, Xu S, Song L, Chen Y, Zhang Y, Zeng F, Wei S, Chen S, Liu L, Xiong Y, Wang Z, Deng J, Zhang X, Sun Y, Yang D, Zhou C, Yang H, Li Y, Deng L, Xu Q, Fang C, Chen X, Wang J, Li T, Zhang G, Zhou H, Yang N, Zhang Y
doi: 10.1038/s41467-025-67262-x
Lung Cancer
Clinical characteristics and survival of small cell lung cancer with limited or extensive synchronous metastatic spread - A German population-based cancer-registry based cohort study
Lung Cancer
Schliemann A, Waldmann A, Katalinic A, Kim-Wanner SZ, Pritzkuleit R, Twardella D, Bertram S
doi: 10.1016/j.lungcan.2026.109448
Lung Cancer
Achieving an Objective Response Following Two Cycles of Neoadjuvant Chemotherapy Plus Anti-PD-(L)1 Inhibitors Might Predict the Optimal Pathological Response in Resectable Stage II-III Nonsmall Cell Lung Cancer
Clin Lung Cancer
Cao W, Duan H, Shao C, Yan X, Liu H
doi: 10.1016/j.cllc.2025.08.004
Lung Cancer
Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial
Nat Commun
Wang L, Rao C, Wang Q, Huang K, Liu L, Zhao J, Wu Y, Chen J, Qian J, Lu H, Pan S, Nie L, Tang H, Dong H, Jia SD, Zang Y, Chu T, Su C
doi: 10.1038/s41467-026-74241-3
Lung Cancer
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
Lancet Oncol
Zhong H, Wang J, Yang R, Luo Y, Zuo W, Zhang W, Xie C, Li Q, Liu Q, Xu X, Wang Q, Yu Y, Chen Y, Yi T, Min X, Shi J, Yang J, Sun H, Chen H, Shi H, Gao J, Shi J, Zhang B, Chu T, Li K, Han B, CAMPASS Investigators
doi: 10.1016/S1470-2045(26)00049-5